Results 101 to 110 of about 21,053 (285)

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia　― One-Year Data From the Global ETNA-AF Program ―

Circulation Reports
Background This study reports prescribing patterns and the 1-year effectiveness and safety of edoxaban in an Asian cohort of Edoxaban Treatment in routiNe clinical prActice (ETNA)-Atrial Fibrillation (AF) patients.
Jong‐Il Choi, S. Kiatchoosakun, P. Jiampo, H. Tse, Y. Soo, Chun-Chieh Wang, Chang-Hoon Lee, L. Pecen, M. Unverdorben, R. De Caterina, P. Kirchhof   +10 more
semanticscholar   +1 more source

Duplicate Prescription Patterns in Patients With Substance Use Disorders

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT This study sought to investigate the frequency and characteristics of duplicate prescriptions (DPs) in psychiatric inpatients with substance use disorders using a DP classification that differentiates between appropriate DPs (ADPs) and potentially inappropriate DPs (PIDPs). The study was conducted as a monocentric retrospective cross‐sectional
Johannes Heck, Benjamin Krichevsky, Martin Schulze Westhoff, Konstantin Fritz Jendretzky, Martin Klietz, Stephan Greten, Alexander Glahn, Stefan Bleich, Sebastian Schröder   +8 more
wiley   +1 more source

Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation

Journal of Pharmaceutical Health Care and Sciences
Background Edoxaban is used as an anti-coagulant to prevent cardioembolic infarction, deep vein thrombosis, and pulmonary embolism. Edoxaban pharmacokinetics have been reported to be affected by several factors such as renal function, age, body weight ...
Satoshi Ueshima, Daiki Hira, Sayana Matsuda, Rio Michihata, Yohei Tabuchi, Tomoya Ozawa, Hideki Itoh, Moritake Iguchi, Masaharu Akao, Takanori Aizawa, Asami Kashiwa, Satoshi Shizuta, Takeru Makiyama, Yoshihisa Nakagawa, Minoru Horie, Tomohiro Terada, Toshiya Katsura   +16 more
doaj   +1 more source

Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1431-1442, February 2026.
Abstract Introduction Atrial fibrillation (AF) carries residual thromboembolic and cardiovascular risk despite oral anticoagulation (OAC). The stress hyperglycaemia ratio (SHR), derived from admission glucose and glycated haemoglobin (HbA1c), integrates information on both acute glycaemic fluctuations and chronic glycaemic burden.
Eva Soler‐Espejo, Yang Chen, José Miguel Rivera‐Caravaca, José Antonio Sánchez‐Salas, María Asunción Esteve‐Pastor, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Response to ‘Re: Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials’ [PDF]

, 2014
We estimated and compared the risk of clinically identified acquired drug resistance under immediate initiation [the currently recommended antiretroviral therapy (ART) initiation strategy], initiation with CD4 cell count less than 500 cells/μl and ...
Boender, TS, Bucher, HC, Dunn, D, Egger, M, Garcia, F, Glass, TR, Günthard, HF, Hawkins, D, Hernán, MA, HIV-CAUSAL Collaboration, ., Jose, S, Lodi, S, Logan, R, Monge, S, Moreno, S, Paraskevis, D, Phillips, AN, Porter, K, Reiss, P, Sabin, C, Scherrer, AU, Schneider, M-P, Simeon, M, van Sighem, A, Vourli, G   +24 more
core   +3 more sources

The Desirable Effects of Edoxaban on Thrombi in the Left Atrium Are Seemingly Connected to Pulmonary Vein Thrombi

Cureus
Ischemic stroke (IS) causes various degrees of disability that sometimes induce social problems: therefore, preventing the occurrence and recurrence of IS is important. The recovery of motor function has been extensively studied.
Hidekazu Takeuchi
semanticscholar   +1 more source

A Multicenter Prospective Cohort Study on the Use of Weight‐Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer‐Associated Venous Thromboembolism—The WAVe Study

American Journal of Hematology, Volume 101, Issue 1, Page 79-88, January 2026.
The WAVe stdudy‐ A multicenter prospective cohort study of wieght‐adjusted dalteparin in patients over 90 kg with acute cancer‐associated venous thromboembolism. ABSTRACT Patients with cancer‐associated thrombosis (CAT) are commonly treated with low‐molecular‐weight heparin (LMWH), but whether dose capping is needed in patients over 90 kg is unclear ...
Tzu‐Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D'Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier   +14 more
wiley   +1 more source

Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2–ERK 1/2 pathway

PLoS ONE
Hepatic ischemia-reperfusion injury causes liver damage during surgery. In hepatic ischemia-reperfusion injury, the blood coagulation cascade is activated, causing microcirculatory incompetence and cellular injury.
Koki Maeda, N. Kuriyama, D. Noguchi, T. Ito, Kazuyuki Gyoten, A. Hayasaki, T. Fujii, Y. Iizawa, Y. Murata, A. Tanemura, M. Kishiwada, S. Mizuno   +11 more
semanticscholar   +1 more source

Delayed Respiratory Failure After Sulfuric Acid Mist Inhalation From a Foaming Lead‐Acid Battery

Acute Medicine &Surgery, Volume 13, Issue 1, January/December 2026.
Delayed, progressive lung injury developed after sulfuric acid mist inhalation from a car battery. The patient improved with multimodal care including corticosteroids. This case highlights the need for vigilance in clinical progression and suggests that corticosteroid therapy may be considered in selected severe cases. ABSTRACT Background Sulfuric acid
Rio Saruta, Yuya Suzuki, Kasumi Satoh, Komei Kameyama, Manabu Okuyama, Hajime Nakae   +5 more
wiley   +1 more source

Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism

Thrombosis Journal
Background Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence.
Masashi Yoshida, Kentaro Ejiri, Naoaki Matsuo, Takanori Naito, Kazuhiro Kuroda, Koji Tokioka, Kunihiko Hatanaka, Ryohei Fujimoto, Hidenaru Yamaoka, Yutaka Kajikawa, Kazuki Suruga, Hiroki Sugiyama, Tsuyoshi Miyaji, Yoshimasa Morimoto, Nobuhiro Okamura, Toshihiro Sarashina, Satoshi Akagi, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Ito, Shinsuke Yuasa   +20 more
doaj   +1 more source